- Home
- WYY vs NRXP Comparison
WYY vs NRXP Comparison
Compare WYY & NRXP Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | WYY | NRXP |
|---|---|---|
| Founded | 1991 | 2015 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | EDP Services | Biotechnology: Pharmaceutical Preparations |
| Sector | Technology | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 60.7M | 63.5M |
| IPO Year | 1998 | N/A |
Fundamental Metrics
Financial Performance| Metric | WYY | NRXP |
|---|---|---|
| Price | $5.41 | $2.56 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 3 | 6 |
| Target Price | $8.67 | ★ $30.50 |
| AVG Volume (30 Days) | 30.5K | ★ 519.3K |
| Earning Date | 11-13-2025 | 11-17-2025 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | ★ $145,926,414.00 | $242,000.00 |
| Revenue This Year | $5.20 | N/A |
| Revenue Next Year | $15.39 | $821.75 |
| P/E Ratio | N/A | N/A |
| Revenue Growth | ★ 9.62 | N/A |
| 52 Week Low | $2.19 | $1.41 |
| 52 Week High | $7.55 | $6.01 |
Technical Indicators
Market Signals| Indicator | WYY | NRXP |
|---|---|---|
| Relative Strength Index (RSI) | 26.04 | 56.82 |
| Support Level | $5.72 | $1.96 |
| Resistance Level | $6.05 | $2.52 |
| Average True Range (ATR) | 0.38 | 0.18 |
| MACD | -0.12 | 0.05 |
| Stochastic Oscillator | 12.72 | 93.55 |
Price Performance
Historical ComparisonAbout WYY WidePoint Corporation
WidePoint Corp is a provider of Technology Management as a Service (TMaaS) that consists of federally certified communications management, identity management, interactive bill presentment and analytics, and an Information Technology as a Service solution. Its solutions include Telecom Lifecycle Management, Digital billing communications solutions, and Mobile and Identity management. Geographically, the company generates a majority of its revenue from the United States and the rest from Europe.
About NRXP NRX Pharmaceuticals Inc.
NRX Pharmaceuticals Inc is a clinical-stage, small-molecule pharmaceutical company that develops and plans to distribute novel therapeutics for the treatment of central nervous system disorders and life-threatening pulmonary diseases. It has announced the commercialization of ZYESAMI (Aviptadil), an application for COVID-related respiratory failure. The company is also developing NRX-100/101, the first sequential drug regimen for bipolar depression in patients with acute suicidal ideation and behavior.